Prescription and Nonprescription hair shampoos, lotions and conditioners. 2. Hairpiece or wigs, hair transplant and drugs such as Monoxide for prominent loss. American consumers spend about $1. 3 billion annually for these treatments. Case Problem: What unit and dollar sales potential for the product category as a whole might be expected now that Monoxide treatment for hair Rexroth no longer required for prescription?
Also how might the loss of US patent protection and marketing exclusivity that Regain had enjoyed since its introduction and competition from generic products affect sales of the Regain brand? Alternative Solution: 1 . Sell the new unpreserved product with 2% monoxide at cheaper price to tackle the competition from fellow sellers. 2. Rebinding:over The Counter sell Selected Solution: Since company has been In this market for a long time now, they have an edge over the new emerging companies.
As far as selected solution is considered, I would suggest them to mix up both the solution and implement it. Since till date they had the patent to manufacture and sell the medicine, they charged the customers much higher than cost price. But now since the exclusivity period is over, they will have to reduce the price (as suggested to be around $29. 50) and promote their product as a cheap and easily available(ETC) medicine.
Also that the medicine can now be sold without prescription also, they can target mega stores and other retail stores. BY attaches and The Upshot Company of US in 1995. Pharmaceutical products account for 90% of company sales; almost 70% of company sales are made outside USA. Industry Profile: Hairpiece or wigs, hair transplant and drugs such as Monoxide for prominent loss. 1 . Sell the new unprejudiced product with 2% monoxide at cheaper price to tackle the Since company has been in this market for a long time now, they have an edge over